

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis and Evaluation of Antiviral Activity of 3'-C-Cyano-3'-Deoxynucleosides

María-José Camarasa^a; Angel Díaz-Ortiz^a; Ana Calvo-hateo^a; Pederico G. De las Heras^a; Jan Balzarini^b; Erik de Clercq^b

^a Instituto de Química Médica, Madrid, Spain ^b Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

To cite this Article Camarasa, María-José, Díaz-Ortiz, Angel, Calvo-hateo, Ana, Heras, Pederico G. De las, Balzarini, Jan and de Clercq, Erik (1989) 'Synthesis and Evaluation of Antiviral Activity of 3'-C-Cyano-3'-Deoxynucleosides', *Nucleosides, Nucleotides and Nucleic Acids*, 8: 5, 837 – 840

To link to this Article: DOI: 10.1080/07328318908054225

URL: <http://dx.doi.org/10.1080/07328318908054225>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**SYNTHESIS AND EVALUATION OF ANTIVIRAL ACTIVITY
OF 3'-C-CYANO-3'-DEOXYNUCLEOSIDES**

María-José Camarasa¹, Angel Díaz-Ortiz¹, Ana Calvo-Mateo¹,
Federico G. De las Heras¹, Jan Balzarini², Erik de Clercq².














¹Instituto de Química Médica, Juan de la Cierva 3, 28006-Madrid, Spain.

²Rega Institute for Medical Research, Katholieke Universiteit Leuven,
B-3000 Leuven, Belgium

ABSTRACT. A series of 3'-C-cyano-3'-deoxy and 3'-C-cyano-2',3'-dideoxy-nucleoside analogues of thymidine, uridine, cytidine and adenosine have been prepared. Their antiviral activity was assessed in various assay systems and while none of the compounds proved specifically active against human immunodeficiency virus, some compounds had marked activity against other viruses.

An increasing number of sugar-modified nucleosides show antiviral activity.¹ The 2',3'-dideoxynucleosides, such as 1-3, are among the most potent and selective inhibitors of human immunodeficiency virus (HIV) described so far.^{2,3} Other arabino, acyclic and carbocyclic nucleoside derivatives show significant activities against a variety of viruses.⁴ The branched-chain sugar nucleosides represent a group of derivatives, of which some members show antiviral, anticancer and enzyme-inhibitory activities.⁵⁻⁷ This prompted us to synthesize and evaluate a series of branched-chain sugar nucleoside derivatives of adenosine, cytidine, uracil and thymidine in which the 3'-OH group was replaced by a 3'-C-CN branch.

Reaction of 2',5'-di-O-(*t*-butyldimethylsilyl)-3'-ketonucleoside derivatives of adenosine (4a),⁸ 4-N-acetylcytosine (4d), thymidine (4t),⁹ and uridine (4u),⁸ with sodium cyanide gave in each case, a mixture of the two epimeric nucleoside 3'-cyanohydrins. These cyano-hydrins were deoxygenated at 3'-position by reaction with phenyloxythio-carbonyl chloride and, then, with tributyltin hydride in the presence of AIBN, to afford stereoselectively 3'-C-cyano-3'-deoxy-β-D-xylo-pento-furanosyl nucleosides 5a, 5d, 5t and 5u.

1a . c . g . t ; R=H2g . t ; R=N₃3c . t4a . d . t . u5a . d . t . u6a . c . d . t . u ; R=H7a . c . t . u8a . c . d . u ; R=H9t .10t ; R=H11t .12t ; R=H13t .14t ; R=H

a, B = Adenin-9-yl;

c, B = cytosin-1-yl;

d, B = 4-N-acetylcytosin-1-yl; g, B = guanin-9-yl

t, B = thymine-1-yl;

u, B = uracil-1-yl

These β -D-xylo-nucleosides were epimerized to the corresponding β -D-ribo epimers 7a-u by treatment with a methanolic NaOH solution up to pH 9. Treatment of the 2',5'-di-O-(t-butyldimethylsilyl)-protected nucleosides 5 and 7 with tetrabutylammonium fluoride gave the corresponding 3'-C-cyano-3'-deoxy- β -D-xylo and ribo deprotected nucleosides 6 and 8, respectively.

The β -D-xylo-thymidine 6t was transformed to the β -D-threo-thymidine 10t by selective 5'-O-silylation with t-butyldimethylsilyl chloride, 2'-deoxygenation with phenyloxythiocarbonyl chloride in pyridine and tributyltin chloride/AIBN, and deprotection with 0.1 N HCl.

The β -D-threo-thymidine derivatives 9t and 10t were epimerised to the β -D-erythro-thymidines 11t and 12t by treatment with a solution of NaOH in methanol up to pH 9.

Table 1. Antiviral activity of 3'-C-cyano-3'-deoxynucleosides in different assay systems

Compound	HIV/MT-4		MSV/C3H		VV/PRK		SV/Vero	
	MIC (μ M)	SI	MIC (μ g/ml)	SI	MIC (μ g/ml)	SI	MIC (μ g/ml)	SI
6a	> 1.6	< 1.8	6.6	6	4	50	10	20
6t	> 250	< 0.9	> 250	1	150	3	150	1.3
6u	> 400	1	260	1.5	> 200	1	> 200	< 2
8a	> 1.6	< 2.4	8.5	4.7	4	25	10	10
8c	> 10	< 2.3	43	> 4.7	40	2.5	> 100	< 1
8u	> 80	< 1.8	> 200	1	> 200	1	> 100	2
10t	> 250	1	> 250	1	> 400	1	> 400	1
12t	> 16	< 1.9	> 16	< 5	20	5	> 10	1
14t	> 50	< 0.5	191	> 1.3	> 100	< 2	> 100	1

Reaction of 1-[5'-O-(*t*-butyldimethylsilyl)-3'-C-cyano-3'-deoxy- β -D-xyllo-pentofuranosyl]thymine with phenyloxythiocarbonyl chloride and 4-dimethylaminopyridine, a stronger base than the pyridine used before for the 2'-deoxygenation of **6t**, did not afford the expected 2'-O-thiocarbonyl derivative, but the 3'-C-cyano-2',3'-unsaturated thymidine derivative **13t**. Treatment of the latter with a 0.1 N solution of HCl in methanol afforded the deprotected unsaturated nucleoside **14t**.

The absolute configuration at C-3' of nucleosides 5-12 was unequivocally determined by NOE experiments.

The 3'-C-cyano-3'-deoxynucleosides were evaluated for their antiviral activity in various assay systems (Table 1) : against human immunodeficiency virus (HIV) in human MT-4 lymphocytes, against murine (Moloney) sarcoma virus (MSV) in murine C3H fibroblasts, against vaccinia virus (VV) in primary rabbit kidney (PRK) cells, and against Sindbis virus (SV) in African green monkey kidney (Vero) cells. The minimum inhibitory concentration (MIC), required to reduce virus-induced cytopathogenicity by 50 %, as well as the minimum cytotoxic concentration for the host cells were determined, and the ratio of the

minimum cytotoxic concentration to the minimum antiviral concentration was defined as the selectivity index (SI). From the results presented in Table 1 it is evident that none of the 3'-C-cyano-3'-deoxynucleosides exhibited a selective inhibitory effect on HIV replication. However, compounds **6a** and **8a** caused a marked and selective inhibition of VV and SV replication. They also demonstrated some selectivity in their effects against MSV, and so did **8c** against MSV and **12t** against VV.

Based on the antiviral results obtained here for the 3'-C-cyano-3'-deoxy- β -D-xylo-pentofuranosyl (**6a**) and 3'-C-cyano-3'-deoxy- β -D-ribo-pentofuranosyl (**8a**) derivatives of adenine, it would seem justified to further explore these compounds for their antiviral potential and mode of action.

REFERENCES

- 1 De Clercq, E.; Walker, R.T. Eds. Antiviral Drug Development. A Multidisciplinary Approach. Plenum Press, New York, 1988.
- 2 Mitsuya, H.; Broder, S. Nature 1987, **325**, 773.
- 3 De Clercq, E.; Anticancer Res. 1987, **7**, 1023.
- 4 Robins, R.K.; Revankar, G.R. in ref. 1; p 11.
- 5 Hoshino, H.; Shimizu, N.; Shimada, N.; Takita, T.; Takeuchi, T. J. Antibiotics 1987, **40**, 1078.
- 6 Walton, E.; Jenkins, S.R.; Nutt, R.F.; Holly, F.W. J. Med. Chem. 1969, **12**, 306.
- 7 Acton, E.M.; Goerner, R.N.; Uh, H.S.; Ryan, K.J.; Henry, D.W. J. Med. Chem. 1979, **22**, 518.
- 8 Hansske, F.; Madej, D.; Robins, M.J. Tetrahedron 1984, **40**, 125.
- 9 Calvo-Mateo, A.; Camarasa, M.J.; Díaz-Ortíz, A.; De las Heras, F.G. Tetrahedron Lett. 1988, **29**, 941.